DRI - BIO HUB - FIRST PATIENT NO LONGER
REQUIRES INSULIN THERAPY PAGE UPDATED 12/1/2019
The Diabetes Research Institute received approval from the FDA to begin Phase1/2 human clinical trials for DRI’s new bioengineered medical device DRI- BIO HUB. The initial "one" person trial was performed on August 18, 2015 on a 43 year old female with T1D and within a short span insulin production from the transplanted islets eliminated the need for exogenous insulin .
DRI’s BIO HUB is described as a “mini organ” delivering insulin to changes in BG levels in real time. The BIO HUB attempts to replicate the insulin producing beta cells natural environment providing additional oxygen and helper cells to promote cellular survival and function. These cells are to be protected from the body’s immune system by cellular encapsulation within the body's abdominal fat cell layer called the omentum..
The FDA has given "orphan status" approval to the Diabetes Research Institute to use the BIOHUB as a potential Brittle Type 1 Diabetes Therapy
dA detailed video describing the procedure can be found on our website's Homepage .